Herantis Pharma Oyj
HRPMF · OTC
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.49 | 0.02 | -0.06 | 0.29 |
| FCF Yield | -5.14% | -4.60% | -2.63% | -1.58% |
| EV / EBITDA | -30.08 | -11.93 | 37.99 | -97.73 |
| Quality | ||||
| ROIC | -116.94% | -133.14% | 53.81% | -89.65% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.56 | 1.13 | -0.70 | 0.48 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -15.65% | -107.95% | -70.01% | 74.95% |
| Safety | ||||
| Net Debt / EBITDA | 0.27 | 0.37 | -4.15 | -1.09 |
| Interest Coverage | -2,271.00 | -344.50 | 4.89 | -86.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |